September 2024
Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3
Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases
ProKidney Suspends One Phase 3 CKD Cell Therapy Trial Deemed Surplus for FDA Approval
ProKidney, CKD, cell therapy, Phase 3 trial, FDA approval
Pfizer and Valneva Announce Positive Phase 2 Results for Lyme Disease Vaccine Candidate VLA15
Lyme disease, VLA15, Pfizer, Valneva, vaccine development, tick-borne diseases
Bayer’s Kerendia Demonstrates 16% Reduction in Cardiovascular Risk for Heart Failure Patients
Bayer, Kerendia, cardiovascular risk, heart failure, finerenone, Phase III trial, FINEARTS-HF, MOONRAKER
Dyne Therapeutics Faces Setbacks Despite Promising DMD Study Results
Dyne Therapeutics, Duchenne Muscular Dystrophy (DMD), DELIVER trial, DYNE-251, adverse events, executive departures
Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results
Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development
Breakthrough in Rare Childhood Epilepsies: Praxis’ Relutrigine Exceeds Efficacy Expectations
Praxis Precision Medicines, relutrigine, rare childhood epilepsies, epilepsy treatment, genetic epilepsy, precision medicine.
Recursion Pharmaceuticals’ AI-Driven Drug Development Strategy Fails to Impress Investors
Recursion Pharmaceuticals, AI, drug development, investors, biotech, pharmaceuticals
Unveiling the Future of Biotech: Top 11 Startups to Watch in 2024
Biotech startups, Top biotech companies, Biotechnology industry, Emerging biotech trends, Biotech innovation, Biotech awards
George Medicines Unveils Promising Low-Dose Triple Combination Pill for Hypertension Management
Hypertension, Triple Combination Pill, Low-Dose, Blood Pressure Control, GMRx2, George Medicines